Polyclonal Antibody to CCAAT/Enhancer Binding Protein Beta (CEBPb)
| Code | Size | Price |
|---|
| PAA713Mu01-20ul | 20ul | £82.00 |
Quantity:
| PAA713Mu01-100ul | 100ul | £152.00 |
Quantity:
| PAA713Mu01-200ul | 200ul | £204.00 |
Quantity:
| PAA713Mu01-1ml | 1ml | £464.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CRP2; IL6DBP; LAP; NF-IL6; TCF5; C/EBP-Beta; Liver-Enriched Transcriptional Activator Protein; Nuclear Factor Of Interleukin 6; Interleukin 6-Dependent DNA-Binding Protein
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
CCAAT/Enhancer Binding Protein Beta
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant CCAAT/Enhancer Binding Protein Beta (CEBPb) | RPA713Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||